INTRODUCTION: The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150-300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients' scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9-77.8 years (mean age 47.3±11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0-76.7 years (mean age 51.4±12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected. RESULTS: Patients on TTFields therapy demonstrated improvements in PFS and OS relative to controls (hazard ratio: 0.64, p=0.031; and 0.61, p=0.028 respectively). TTFields average time on therapy was 74.8% (median 82%): median PFS of these patients was 19.75 months. Seven patients with TTFields usage ≤60% (23-60%, mean 46.3%, median 53%) had a median PFS of 7.95 months (p=0.0356). Control patients with no TTFields exposure had a median PFS of 12.45 months. Median OS of TTF patients was 31.67 months compared to 24.80 months for controls. DISCUSSION: This is the most extensive study on newly-diagnosed GBM patients treated with TTFields, covering a period of 18 years at a single center and presenting not only data from clinical trials but also a group of 36 patients treated with TTFields as a part of routine clinical practice.

Department of Neurosurgery Faculty Hospital Ostrava Ostrava Czechia

Department of Neurosurgery Na Homolce Hospital Prague Czechia

Department of Pathology Na Homolce Hospital Prague Czechia

Department of Radiation Oncology Central Military Hospital and Faculty Hospital Motol Prague Czechia

Department of Radiation Oncology Masaryk Memorial Cancer Institute and Faculty of Medicine Masaryk University Brno Czechia

Department of Radiology and Department of Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czechia

Zobrazit více v PubMed

Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA (2013) 310(17):1842–50. doi: 10.1001/jama.2013.280319 PubMed DOI

Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin (2020) 70(4):299–312. doi: 10.3322/caac.21613 PubMed DOI

Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res (2000) 6(7):2585–97. PubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352(10):987–96. doi: 10.1056/NEJMoa043330 PubMed DOI

Lakomy R, Kazda T, Selingerova I, Poprach A, Pospisil P, Belanova R, et al. . Real-world evidence in glioblastoma: Stupp’s regimen after a decade. Front Oncol (2020) 10:840. doi: 10.3389/fonc.2020.00840 PubMed DOI PMC

Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. . The epidemiology of glioma in adults: A ‘state of the science’ review. Neuro Oncol (2014) 16(7):896–913. doi: 10.1093/neuonc/nou087 PubMed DOI PMC

Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM. Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: A systematic review and meta-analysis. Sci Rep (2020) 10(1):11622. doi: 10.1038/s41598-020-68011-4 PubMed DOI PMC

Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. . Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA (2017) 318(23):2306. doi: 10.1001/jama.2017.18718 PubMed DOI PMC

Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci (2018) 54:7–13. doi: 10.1016/j.jocn.2018.05.002 PubMed DOI

Kirson ED, Dbalý V, Tovaryš F, Vymazal J, Soustiel JF, Itzhaki A, et al. . Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. PNAS (2007) 104(24):10152–7. doi: 10.1073/pnas.0702916104 PubMed DOI PMC

Hart FX, Palisano JR. The application of electric fields in biology and medicine. In: Kandelousi MS, editor. Electric field. InTech; (2018). Available at: http://www.intechopen.com/books/electric-field/the-application-of-electric-fields-in-biology-and-medicine.

NovoCure Ltd . Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma. In: Clinicaltrials.gov (2022). Available at: https://clinicaltrials.gov/ct2/show/NCT03377491.

Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. (2013) 81(3):445–50. doi: 10.1016/j.lungcan.2013.06.025 PubMed DOI

Ceresoli GL, Aerts JG, Dziadziuszko R, Cedres S, Hiddinga B, Meerbeeck JPV, et al. . STELLAR: Final updated results of a phase II trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma. Ann Oncol (2019) 30:ii72. doi: 10.1093/annonc/mdz069 DOI

Lyman GH. Comparative effectiveness research in oncology. Oncologist (2013) 18(6):752–9. doi: 10.1634/theoncologist.2012-0445 PubMed DOI PMC

Wick W. TTFields: Where does all the skepticism come from? Neuro-Oncology (2016) 18:303–5. doi: 10.1093/neuonc/now012 PubMed DOI PMC

Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 8(7):1277–80. doi: 10.1200/JCO.1990.8.7.1277 PubMed DOI

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 28(11):1963–72. doi: 10.1200/JCO.2009.26.3541 PubMed DOI

Fabian D, Guillermo Prieto Eibl MdP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, et al. . Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review. Cancers (Basel) (2019) 11(2):174. doi: 10.3390/cancers11020174 PubMed DOI PMC

Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncology/Hematology. (2017) 111:60–5. doi: 10.1016/j.critrevonc.2017.01.005 PubMed DOI

Raj R, Seppä K, Luostarinen T, Malila N, Seppälä M, Pitkäniemi J, et al. . Disparities in glioblastoma survival by case volume: a nationwide observational study. J Neurooncol. (2020) 147(2):361–70. doi: 10.1007/s11060-020-03428-5 PubMed DOI PMC

Kelly C, Majewska P, Ioannidis S, Raza MH, Williams M. Estimating progression-free survival in patients with glioblastoma using routinely collected data. J Neurooncol. (2017) 135(3):621–7. doi: 10.1007/s11060-017-2619-1 PubMed DOI PMC

Regev O, Merkin V, Blumenthal DT, Melamed I, Kaisman-Elbaz T. Tumor-treating fields for the treatment of glioblastoma: a systematic review and meta-analysis. Neurooncol Pract (2021) 8(4):426–40. doi: 10.1093/nop/npab026 PubMed DOI PMC

Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: A subgroup analysis of the EF-14 phase III trial. J Neurooncol. (2019) 141(2):467–73. doi: 10.1007/s11060-018-03057-z PubMed DOI PMC

Szomolanyi P, Rohrer M, Frenzel T, Noebauer-Huhmann IM, Jost G, Endrikat J, et al. . Comparison of the relaxivities of macrocyclic gadolinium-based contrast agents in human plasma at 1.5, 3, and 7 T, and blood at 3 T. Invest Radiol (2019) 54(9):559–64. doi: 10.1097/RLI.0000000000000577 PubMed DOI PMC

Kazda T, Bulik M, Pospisil P, Lakomy R, Smrcka M, Slampa P, et al. . Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging. NeuroImage Clin (2016) 11:316–21. doi: 10.1016/j.nicl.2016.02.016 PubMed DOI PMC

Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis